Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of Neoadjuvant Chemoradiation With Pembrolizumab Followed by Pembrolizumab With Lenvatinib in Esophageal/Gastroesophageal Junction Squamous Cell and Adenocarcinomas

NCT04929392 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT04929392
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04929392 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of Neoadjuvant Chemoradiation With Pembrolizumab Followed by Pembrolizumab With Lenvatinib in Esophageal/Gastroesophageal Junction Squamous Cell and Adenocarcinomas
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 25, 2022
Completion date
April 25, 2027
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage i gastroesophageal junction adenocarcinoma ajcc v8, clinical stage ii gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iia gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iib gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iii gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iva gastroesophageal junction adenocarcinoma ajcc v8, esophageal adenocarcinoma, esophageal squamous cell carcinoma, pathologic stage i gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage ia gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage ib gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage ic gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage ii gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iia gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iib gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iiia gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iiib gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iv gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iva gastroesophageal junction adenocarcinoma ajcc v8